Conv. Plasma
Nigella Sativa
Peg.. Lambda

All bebtelovimab studies
Meta analysis
Home COVID-19 treatment researchBebtelovimabBebtelovimab (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality 86% Improvement Relative Risk Death/hospitalization 43% Hospitalization 29% Bebtelovimab  Dryden-Peterson et al.  EARLY TREATMENT Is early treatment with bebtelovimab beneficial for COVID-19? Retrospective 754 patients in the USA (March - May 2022) Lower mortality (p=0.25) and death/hosp. (p=0.14), not sig. Dryden-Peterson et al., Open Forum Inf.., Oct 2022 Favors bebtelovimab Favors control

Bebtelovimab for high-risk outpatients with early COVID-19 in a large US health system

Dryden-Peterson et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac565
Oct 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 377 outpatients in the USA and matched controls, showing lower hospitalization/mortality with bebtelovimab treatment, without statistical significance. Notably, none of the patients that died in the control group were hospitalized within 14 days (later hospitalization is not reported). There may be a difference in the populations in terms of propensity to receive SOC.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BQ.1.1 Planas.
risk of death, 85.7% lower, RR 0.14, p = 0.25, treatment 0 of 377 (0.0%), control 3 of 377 (0.8%), NNT 126, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of death/hospitalization, 43.0% lower, RR 0.57, p = 0.14, treatment 10 of 377 (2.7%), control 17 of 377 (4.5%), NNT 54.
risk of hospitalization, 28.6% lower, RR 0.71, p = 0.53, treatment 10 of 377 (2.7%), control 14 of 377 (3.7%), NNT 94.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Dryden-Peterson et al., 27 Oct 2022, retrospective, USA, peer-reviewed, 7 authors, study period 16 March, 2022 - 31 May, 2022, average treatment delay 3.0 days.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperBebtelovimabAll
Bebtelovimab for high-risk outpatients with early COVID-19 in a large US health system
MD, MSc Scott Dryden-Peterson, BS Andy Kim, MS Mary-Ruth Joyce, MD Jennifer A Johnson, MD Arthur Y Kim, MD Lindsey R Baden, MD, MPH Ann E Woolley
There are limited data for the clinical efficacy of bebtelovimab in preventing severe COVID-19. Among outpatients unable to take nirmatrelvir-ritonavir at a large health system, 10 of 377 (2.7%) patients who received bebtelovimab and 17 of 377 (4.5%) matched untreated patients were hospitalized or died. The 43% observed risk reduction with bebtelovimab was not statistically significant (p = 0.14).
Author contributions. S.D.P. and A.E.W. designed the study. S.D.P., A.K., M.J., and A.E.W. collected and adjudicated the data. S.D.P., J.A.J., A.Y.K., L.R.B., and A.E.W. provided scientific interpretation of the data. S.D.P. and A.E.W. performed the statistical analysis. S.D.P., A.K., M.J., and A.E.W. had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. S.D.P. and A.E.W. drafted the manuscript. All
Aggarwal, Beaty, Bennett, Carlson, Ginde, Change in Effectiveness of Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients During the Omicron Phase, Medrxiv. Published, doi:10.1101/2022.06.17.22276575
Dougan, Azizad, Chen, Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19, Medrxiv. Published, doi:10.1101/2022.03.10.22272100
Dougan, Nirula, Azizad, Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19, New Engl J Med, doi:10.1056/nejmoa2102685
Dryden-Peterson, Kim, Kim, Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system, Published online, doi:10.1101/2022.06.14.22276393
Ganatra, Dani, Ahmad, Oral Nirmatrelvir and Ritonavir in Non-hospitalized Vaccinated Patients with Covid-19, Clin Infect Dis Official Publ Infect Dis Soc Am. Published, doi:10.1093/cid/ciac673
Ganesh, Philpot, Bierle, Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab among High-Risk Patients with Mild to Moderate Coronavirus Disease 2019, J Infect Dis, doi:10.1093/infdis/jiab377
Gupta, Gonzalez-Rojas, Juarez, Early Treatment for Covid-19 with SARS-CoV-2
Halekoh, Højsgaard, Yan, The R Package geepack for Generalized Estimating Equations, J Stat Softw, doi:10.18637/jss.v015.i02
Khare, Gurry, Freitas, GISAID's Role in Pandemic Response, China Cdc Wkly, doi:10.46234/ccdcw2021.255
Liang, Zeger, Longitudinal data analysis using generalized linear models, Biometrika
Razonable, Horo, Hanson, Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease
Rubin, Liu, Giobbie-Hurder, Performance of a Triage Protocol for Monoclonal Antibodies in a Mixed Vaccinated and Unvaccinated Cohort of COVID-19 Patients Treated With Intravenous Infusion or Subcutaneous Injection, Open Forum Infect Dis, doi:10.1093/ofid/ofac182
Takashita, Yamayoshi, Simon, Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12, New Engl J Med. Published, doi:10.1056/nejmc2207519
Weinreich, Sivapalasingam, Norton, REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19, New Engl J Med, doi:10.1056/nejmoa2035002
Yetmar, Beam, Horo, Outcomes of Bebtelovimab and Sotrovimab Treatment of Solid Organ Transplant Recipients with Mild-to-moderate COVID-19 during the Omicron Epoch, Transpl Infect Dis. Published, doi:10.1111/tid.13901
Zou, A Modified Poisson Regression Approach to Prospective Studies with Binary Data, American Journal of Epidemiology, doi:10.1093/aje/kwh090
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop